CRM1 inhibitors such as leptomycin B and selinexor, which has obtained FDA approval for the treatment of adult patients with multiple myeloma, could potentially be effective in NUP98‐r AML.62, 129, 168. Here, NUP98 is linked to acute myeloid leukemia.